RNA 3' readthrough of oncoretrovirus and lentivirus: implications for vector safety and efficacy.
about
Overlapping enhancer/promoter and transcriptional termination signals in the lentiviral long terminal repeatALDH isozymes downregulation affects cell growth, cell motility and gene expression in lung cancer cells3' end mRNA processing: molecular mechanisms and implications for health and diseaseAlteration of T cell immunity by lentiviral transduction of human monocyte-derived dendritic cellsNon-integrative lentivirus drives high-frequency cre-mediated cassette exchange in human cellsOptimized lentiviral vector design improves titer and transgene expression of vectors containing the chicken beta-globin locus HS4 insulator element.Mechanism of reduction in titers from lentivirus vectors carrying large inserts in the 3'LTR.Bacterial delivery of nuclear proteins into pluripotent and differentiated cellsGammaretroviral vectors: biology, technology and applicationEx vivo development, expansion and in vivo analysis of a novel lineage of dendritic cells from hematopoietic stem cellsNotable reduction in illegitimate integration mediated by a PPT-deleted, nonintegrating lentiviral vector.Influence of untranslated regions on retroviral mRNA transfer and expressionInhibition of histone deacetylation in 293GPG packaging cell line improves the production of self-inactivating MLV-derived retroviral vectorsRescue of splicing-mediated intron loss maximizes expression in lentiviral vectors containing the human ubiquitin C promoter.Occurrence of leukaemia following gene therapy of X-linked SCID.Evaluation of residual promoter activity in γ-retroviral self-inactivating (SIN) vectors.Whole transcriptome characterization of aberrant splicing events induced by lentiviral vector integrations.Suppression of spermatogenesis by bisdichloroacetyldiamines is mediated by inhibition of testicular retinoic acid biosynthesisVector design for expression of O6-methylguanine-DNA methyltransferase in hematopoietic cells.Controlled and localized genetic manipulation in the brain.Stable gammaretroviral vector expression during embryonic stem cell-derived in vitro hematopoietic development.Reducing the genotoxic potential of retroviral vectors.Direct reprogramming of fibroblasts to myocytes via bacterial injection of MyoD proteinT-cell receptor gene transfer by lentiviral vectors in adoptive cell therapy.Combinatorial incorporation of enhancer-blocking components of the chicken beta-globin 5'HS4 and human T-cell receptor alpha/delta BEAD-1 insulators in self-inactivating retroviral vectors reduces their genotoxic potential.Integration-deficient lentiviral vectors: a slow coming of age.Lentiviral vectors for immune cells targeting.The use of chromatin insulators to improve the expression and safety of integrating gene transfer vectorsBiosafety features of lentiviral vectorsPutting an 'End' to HIV mRNAs: capping and polyadenylation as potential therapeutic targets.A self-deletion lentiviral vector to reduce the risk of replication-competent virus formation.Lentiviral vectors and cystic fibrosis gene therapyViral Vectors: The Road to Reducing Genotoxicity.Lentiviral siRNAs targeting multiple highly conserved RNA sequences of human immunodeficiency virus type 1.Diverse T-cell differentiation potentials of human fetal thymus, fetal liver, cord blood and adult bone marrow CD34 cells on lentiviral Delta-like-1-modified mouse stromal cells.Overcoming promoter competition in packaging cells improves production of self-inactivating retroviral vectors.Two distinct Moloney murine leukemia virus RNAs produced from a single locus dimerize at random.Dynamic DNA methylation and histone modifications contribute to lentiviral transgene silencing in murine embryonic carcinoma cellsSelf-inactivating retroviral vectors with improved RNA processing.Functional transfer of CD40L gene in human B-cell precursor ALL blasts by second-generation SIN lentivectors.
P2860
Q21245196-429F704E-CF57-4C6C-A4CD-A44104DF8BB1Q24569826-B82388EE-8A6D-4F59-9F7E-CAC04484D5B7Q24648650-7B58D1DE-A56E-4277-8E46-F4C03E98EAD7Q24799218-7EE1C1F7-9B48-408E-AD8E-F190E3E09D79Q28478217-31FD6CC9-2E3D-49A0-942A-6C2D44EA697AQ33713427-2C2190A3-26AE-4221-90D8-A9EB5B8EA31EQ33713951-4B09FC49-9683-4B1A-9D22-B6B8B98AB98DQ33815158-53F4935B-BE97-4001-B65A-4A2FE032D1D3Q34223822-78BB6497-0A14-478D-8C04-B658F2E90949Q34419349-4F491E88-3803-4502-9FD2-4A4710839D1FQ34621737-19DA0894-1D6B-4616-A8E6-C790964B4202Q34668961-932BE000-4C32-41C4-A87D-5CFDD4140ECEQ34715929-DF6C8B6A-2B4B-49A8-AADB-CB3A73EC5D51Q34883547-B4CF8D79-FC14-4E83-A0D3-FEB9C901BE2CQ35166805-84F39A1C-7CDA-4730-B942-B16EBCA5CDD2Q35665234-C27C3934-F20C-4F06-8284-69ABE940BEC6Q35913748-72BE881D-6B85-47BA-99AD-919518569FE7Q36018454-07B786E0-FC80-463A-B0FB-A3FB117686D9Q36248825-60A52B4B-9932-4903-B449-7E656EAFB095Q36517060-CC8027D5-6792-4F2C-97CB-36CC4A9A87B7Q36665437-6456A629-8A0A-434D-9A77-01C196F98A04Q36670724-26D30E45-ED29-4EEE-AA70-994CD66CF8ADQ36739956-7ACE4393-C436-4789-AA84-6821CF5111E1Q36842738-745EF818-ADE1-413F-BA31-D227B0B6F63BQ37021156-557197F7-352E-408B-8BD7-50C368AB51EBQ37506025-299E0BC9-13DF-4C01-875F-71D1242A000BQ37677792-432C176F-B20C-4CE5-AEBA-026A409519E6Q37830029-334BE834-A01A-40DB-B142-D4B564F6824CQ38073294-BE9B7018-9B7B-40BB-A80A-0C3EFBCCDD7CQ38170575-74FADD80-A8CE-4C94-9D71-D820B0D71132Q38317683-3F7F3F36-0F7E-4940-8CDE-14A94481149AQ38614351-43C9C00F-8AFB-4FA1-8804-78BB06882A31Q38800643-BDB9C56A-7C72-4789-992D-DFC95A3FF694Q38938529-90662760-542B-42CF-9936-2ABF9318A7ACQ39796195-1FD1C4FE-E918-4D46-857B-AE6DA33617CAQ40269711-6AC25AC8-9133-4071-8FE3-09C863D08D85Q40363526-54BB49AC-296B-45EF-97C3-6F0562FFE6E9Q40381057-370D76FA-0CB6-4430-AE25-3D9A42DAA63EQ40515056-05AF6719-84F6-4D27-9BE4-8871D1AA91FFQ40606291-F996623B-EC87-4AA3-ABF1-EE23425D546F
P2860
RNA 3' readthrough of oncoretrovirus and lentivirus: implications for vector safety and efficacy.
description
2002 nî lūn-bûn
@nan
2002 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
name
RNA 3' readthrough of oncoretr ...... or vector safety and efficacy.
@ast
RNA 3' readthrough of oncoretr ...... or vector safety and efficacy.
@en
RNA 3' readthrough of oncoretr ...... or vector safety and efficacy.
@nl
type
label
RNA 3' readthrough of oncoretr ...... or vector safety and efficacy.
@ast
RNA 3' readthrough of oncoretr ...... or vector safety and efficacy.
@en
RNA 3' readthrough of oncoretr ...... or vector safety and efficacy.
@nl
prefLabel
RNA 3' readthrough of oncoretr ...... or vector safety and efficacy.
@ast
RNA 3' readthrough of oncoretr ...... or vector safety and efficacy.
@en
RNA 3' readthrough of oncoretr ...... or vector safety and efficacy.
@nl
P2093
P2860
P1433
P1476
RNA 3' readthrough of oncoretr ...... or vector safety and efficacy.
@en
P2093
Anne-Kathrin Zaiss
Lung-Ji Chang
Sodany Son
P2860
P304
P356
10.1128/JVI.76.14.7209-7219.2002
P407
P577
2002-07-01T00:00:00Z